Reverse Settlement Bill Clears House Subcommittee With GAO Report Attached

Legislation that would prohibit brand companies from compensating generic companies to delay entry of their generic drugs cleared the House Subcommittee on Commerce, Trade and Consumer Protection with a caveat: a Government Accountability Office report will keep tabs on whether the act results in earlier or delayed entry of generics to the market